- Home
- AVB vs ROIV Comparison
AVB vs ROIV Comparison
Compare AVB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVB | ROIV |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 20.7B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AVB | ROIV |
|---|---|---|
| Price | $169.54 | $28.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $198.20 | $27.56 |
| AVG Volume (30 Days) | 948.5K | ★ 4.2M |
| Earning Date | 04-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.40 | N/A |
| Revenue | ★ $3,040,725,000.00 | $29,053,000.00 |
| Revenue This Year | $4.04 | N/A |
| Revenue Next Year | $5.03 | $878.32 |
| P/E Ratio | $22.76 | ★ N/A |
| Revenue Growth | ★ 4.36 | N/A |
| 52 Week Low | $160.10 | $9.87 |
| 52 Week High | $213.34 | $30.33 |
Technical Indicators
Market Signals| Indicator | AVB | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 54.52 |
| Support Level | $167.78 | $26.45 |
| Resistance Level | $181.72 | $30.33 |
| Average True Range (ATR) | 2.94 | 0.94 |
| MACD | 1.10 | 0.02 |
| Stochastic Oscillator | 91.01 | 80.38 |
Price Performance
Historical ComparisonAbout AVB AvalonBay Communities Inc.
AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.